Fat metabolism research fragment
AOD-9604.
3 vendors · ¥3949–8041
Modified C-terminal fragment of human growth hormone (hGH 177–191). Researched for adipose-tissue mechanisms; not approved for human therapeutic use.
Live vendor register · grouped by strength
Every vendor. Cheapest per mg first, kits listed separately.
AOD-9604 · price per mg
3 listings · unflagged vendors first · Listings data last updated October 2026
Best price per mg: Pepsup 5 mg at ¥1,259/mg.
2 mg
1 listing01
Pharma Lab GlobalVID-PHARMA-L · UK dispatch · from £18.86
2 mg
99%
HPLC certificates
In stock
10–14 days
¥1,975/mg
¥3,949
5 mg
2 listings01
PepsupVID-PEPSUP · €34.99 · duties on delivery
5 mg
99%
No COA published (mfr claim 99%+)
In stock
NL dispatch · PostNL Tracked 2–5 business days
¥1,259/mg
¥6,293
02
Particle PeptidesVID-PARTICLE · SK dispatch · €44.71 ex-VAT
5 mg
99.8%
Liquilabs (CZ) · batch 2025256, published 2025-08-13 · HPLC · FTIR · microbial counts · endotoxin · elemental impurities · purity >99.8% · no MS identity on this reportLiquilabs · HPLC · FTIR · TAMC/TYMC · LAL · Elemental impurities · Batch 2025256 · Aug 13, 2025
In stock
DHL Express 2–3 days (€50) · Slovak Post 5–7 days (€45)
¥1,608/mg
¥8,041
Same research area
Similar compounds.
GH secretagogue research
Ipamorelin
Synthetic pentapeptide described in 1998 by Novo Nordisk researchers as a selective ghrelin/GH-secretagogue receptor agonist; researched for growth-hormone release. Not approved for human therapeutic use.
4 vendors¥2698–4824
GHRH analogue research
CJC-1295
GHRH(1-29) analogue developed by ConjuChem; the DAC form binds albumin and persists for days, the no-DAC form (Mod GRF 1-29) is short-acting. Researched for GH/IGF-1 stimulation; not approved for human therapeutic use.
4 vendors¥3866–9942
Triple hormone agonist research
Retatrutide
Investigational triple GIP/GLP-1/glucagon receptor agonist (LY3437943) developed by Eli Lilly and studied in Phase 3 trials; not approved as a medicine anywhere and not for human therapeutic use.
2 vendors¥12588–21931
GIP/GLP-1 dual agonist research
Tirzepatide
Dual GIP/GLP-1 receptor agonist, FDA- and EMA-approved as Mounjaro and Zepbound. Research-vial tirzepatide is a different, unapproved product, not made or reviewed as those medicines, and not for human use.
1 vendor¥16185
Long-form research guide
Weight Loss Research. Mechanism + protocols + safety.
Lipolysis, GH secretagogues, and adipose tissue modulation in obesity models
Open the long-form guide for AOD-9604 →